Mind Medicine (MindMed) Inc. (MNMD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Mind Medicine (MindMed) Inc. in 2026. The next earnings report is expected on November 5, 2026.
Next earnings date
05 Nov 2026
In 76 days
EPS estimate
-0.50
Revenue estimate
0
Past earnings
Latest earnings analysis
Mind Medicine (MindMed) Inc. missed consensus estimates in its latest earnings report, with EPS of $-1.44 versus an estimate of $-0.541 and revenue of $0 meeting estimates. In the prior quarter, EPS also fell short of expectations while revenue likewise met estimates.
No dividend history available.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Mind Medicine (MindMed) Inc. (MNMD) is scheduled to report earnings on November 5, 2026.
Mind Medicine (MindMed) Inc. (MNMD) last reported earnings on August 6, 2026.
Mind Medicine (MindMed) Inc. (MNMD) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.